---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-014154"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:27:47.536273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain

## Summary
- DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.
- At week 24, +7.1 letter BCVA gain and 76-micron CST reduction; 73% supplement-free vs 50%.
- Favorable safety: no DURAVYU-related ocular or systemic SAEs, no endophthalmitis or retinal vasculitis.
- Phase 3 non-inferiority pivotal program planned by end of 2025; FDA meeting in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-014154
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/0000950170-25-014154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/eypt-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-014154
- JSON: https://secwatch.observer/filing/0000950170-25-014154.json
- Plain text: https://secwatch.observer/filing/0000950170-25-014154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.